Intarcia Therapeutics

Intarcia creates vice president and global head of regulatory affairs

Thursday, July 18, 2013

Biopharmaceutical company Intarcia Therapeutics has hired Dr. Eddie Li to the newly created position of vice president and global head of regulatory affairs. Li brings more than 20 years of experience in regulatory affairs to Intarcia and will be a member of the executive team overseeing the advancement of ITCA 650 (continuous subcutaneous delivery of exenatide) toward successful registration in key markets around the world. ITCA 650 is the company’s diabetes drug candidate currently in global phase III clinical trials for the treatment for type 2 diabetes.

[Read More]

Foresite closes $100M growth capital fund for late-stage healthcare companies

Friday, February 1, 2013

Foresite Capital Management, a growth equity firm founded by Jim Tananbaum to finance late-stage healthcare companies, has closed its $100 million fund, Foresite Capital Fund I. The firm draws on Tananbaum and his partners’ experience and expertise in building leading healthcare companies, as well as their broad private and public investment experience.

[Read More]